Bo.pdf

Overall research theme:Cardiovascular disease and postmenopausal replacement therapy: Clinical, epidemiological and experimentalstudies Senior staff member(s): Position(s): Department/institution/address/telephone/fax:Department of Obstetrics and Gynaecology, University of CopenhagenH:S Hvidovre Hospital, Kettegaard Allé 30, DK 2650 HvidovreTel.: 3632 3632 Fax: 3632 3361 Characteristics of the research group: Hormone replacement therapy and cardiovascular disease in postmenopausal women.
Both epidemiological and experimental studies indicate a cardioprotective effect of estrogen as well as acombination of estrogen plus progestin on ischemic heart disease. This notion has recently beenquestioned by a randomised clinical trial. The aim of the research team is to elucidate the effect of varioushormone regimens in clinical, biological and epidemiological studies.
Running projects: Titles and abstracts: Torur Dalsgaard
Long term effects of hormone replacement therapy on function of atherosclerotic arteries in heart and
brain.
Claus Otto Lund
Østrogens kardiovaskulære protektive virkning: effekt på cerebrale og koronare resistenskar fra
aterosklerotiske hunkaniner
Morten Beck Sørensen
Postmenopausal hormone replacement therapy and cardiovascular disease
Anette Tønnes Pedersen
Hormone replacement therapy and risk of stroke
Ellen Løkkegaard
The influence of cardiovascular risk factors on the association between hormone replacement therapy and
cardiovascular disease
Claudia Stahlberg
Hormone replacement therapy and breast cancer – The European perspective
Recent publications related to the projects described above:Ottesen B, Pedersen AT. Physiological effects of ovarian hormones: Clinical aspects and compliance. Eur Heart J, 1996;17 Ottesen B, Sorensen MB. Women at cardiac risk: is HRT the route to maintaining cardiovascular health. Int J Gynaecol Obstet Pedersen AT, Lidegaard Ø, Kreiner S, Ottesen B. Hormone replacement therapy and risk of non-fatal stroke. Lancet.
Sørensen MB, Skouby SO, Ottesen BS. Postmenopausal hormonsubstitution og iskæmisk hjertesygdom. Ugeskr Læg Sørensen MB, Rasmussen V, Jensen G, Ottesen B. Temporal changes in clinic and ambulatory blood pressure during cyclic postmenopausal hormone replacement therapy. J Hypert 2000;18:1387-91 Sørensen MB, Fritz-Hansen T, Pedersen AT, Jensen HH, Højgaard L, Ottesen B. Temporal changes in cardiac function and cerebral blood flow during sequential postmenopausal hormone replacement. Submitted. Am J Obstet Gynecol2001;184(2):41-7 Sørensen MB, Rosenfalck AM, Hojgaard L, Ottesen B. Obesity and sarcopenia after menopause are reserved by sex hormone replacement therapy. Obes Res 2001;10:622-6 Dalsgaard T, Larsen CR, Mortensen A, Larsen JJ, Ottesen B. New animal model for the study of postmenopausal coronary and cerebral artery function: the Watanabe heritable hyperlipidemic rabbit fed on a diet avoiding phytoestrogens.
Climacteric 2002;5:178-89 Pedersen AT, Ottesen B. Hormone replacement therapy, stroke and thromboembolism: epidemiological evidence. Martin Dunitz Ltd 2002. The Cromwell Press, Trowbridge Pedersen AT, Ottesen B. Hormonbehandling i overgangsalderen og risiko for kardiovaskulær sygdom. Ugeskr Læg Sørensen MB, Ottesen B. P-piller og risiko for myokardieinfarkt. Ugeskr Læg 2002; 164:2415-16.
Løkkegaard EL, Pedersen AT, Laursen P, Loft IP, Larsen S, Jørgensen TJ. The influence of hormone replacement therapy on the age related change in cognitive performance. Analysis based on a Danish cohorte study. Maturitas. In press.
Løkkegaard EL, Pedersen AT, Ottesen B. Long term effects of hormone replacement therapy: Cardiovascular disease. Reviews in Gynaecological Practice, in press.
Løkkegaard EL, Nielsen LF, Køster A, Garde K. Description of women who choose hormone replacement therapy on cardiovascular risk factors and personality traits. Analyses based on a Danish cohort study. Archives on Women’sMental Health. In press.
Stahlberg C, Pedersen AT, Lynge E, Ottesen B. Hormone Replacement Therapy and Risk of Breast Cancer – the role of progestins. Acta Obst Gynecol Scand. In press.
Dalsgaard T, Hannibal J, Fahrenkrug J, Rifbjerg Larsen CH, Ottesen B. VIP and PACAP display different vascular effects in rabbit coronary and cerebral arteries. Reg Pep. Submitted Dalsgaard T, Mortensen A, Larsen JJ, Ottesen B. Long-term estradiol treatment in atherosclerotic Watanabe-rabbits coronary arteries: Changes in electro-mechanical but not in pharmaco-mechanical response. Submitted Dalsgaard T, Mortensen A, Larsen JJ, Ottesen B. Long-term estradiol treatment improves VIP-mediated vasodilatation in atherosclerotic coronary Watanabe-rabbits arteries. Submitted Dalsgaard T, Mortensen A, Larsen JJ, Ottesen B. Longterm estradiol treatment decreases endothelin induced contraction in atherosclerotic cerebral watanabe rabbit arteries. In prep Pedersen NG, Pedersen S, Dalsgaard T, Nilas L, Ottesen B. Endothelin-1 induced vasoconstriction variates with the progestogen used for pretreatment. In prep Pedersen S, Pederen NG, Dalsgaard T, Nilas L, Ottesen B. Long-term treatment with the progestogens medroxyprogesteroneacetate (MPA) and norethisterone acetate (NETA) displays different vascular effect. In prep.

Source: http://www.dacra.dk/downloads/projects/BO.pdf

reports.fja-cmf.gc.ca

CITATION: PFIZER CANADA INC. V. APOTEX INC., 2009 FCA Apotex Inc. ( Appellant ) ( Respondent ) Pfizer Canada Inc. and Pfizer Ireland Pharmaceuticals ( Respondents ) ( Applicants ) The Minister of Health ( Respondent ) ( Respondent ) INDEXED AS: PFIZER CANADA INC. V. APOTEX INC. (F.C.A.) Federal Court of Appeal, Létourneau, Noël and Blais JJ.A.—Toronto, December 17 and

Wissenschaftl. studien aminosäuren

Wissenschaftliche Studien zur Wirkungsweise von Aminosäuren für Arthrose und Osteoporose 1. Amman, Laib, Bonjour et al. (2002): Dietary essential aminoacid supplements increase tue bone mass & bone microarchitecture in an isocaloric low-Protein diet. Bone Mineral Research 2002 2. Wil iams, J.Z., Abumrad, N. & Barbul, A. (2002): Effect of a Specialized Amino Acid Mixture

Copyright © 2009-2018 Drugs Today